Eosinophil and Anticoagulation in COVID-19 Patients

Completed

• Conditions: COVID-19
• Interventions: Drug: LMWH

• Registration Number: NCT04507282
• Lead Sponsor: Bursa Postgraduate Hospital

Brief Summary

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-15
• Primary Completion: 2020-07-01
• Study Completion: 2020-07-15
• Status Verified: 2020-08
• Study First Submitted: 2020-08-07
• Study First Submitted QC: 2020-08-07
• Study First Posted: 2020-08-11
• Last Update Submitted: 2020-08-15
• Last Update Posted: 2020-08-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH,
• agreed to participate in the study were included

Exclusion Criteria

• Patients with previous coagulopathy,
• continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease),
• glomerular filtration rate (GFR) <30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
COVID 19 positive patients	LMWH	-

Primary Outcome Measures

Name	Time	Method
subprophylactic anticogulation level	14 days	\<0.2IU/ml

Trial Locations

Locations (1)

Bursa Yüksek İhtisas Hastanesi; 🇹🇷 Yıldırım, Turkey